Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain
© 2024. The Author(s)..
PURPOSE: Biomarkers as screening for precision medicine is a fundamental step. The purpose of this article is twofold. First, to highlight the existing barriers in the implementation of Precision Medicine in Spain, with a special emphasis on barriers in access to the determination of biomarkers. Second, to provide a Roadmap that can help implement Precision Medicine equitably at the national level and optimize the use of biomarkers.
METHODS: A systematic review of literature (SRL) and a focus group (FG) with multidisciplinary experts has been carried out in 2023. Participants were contacted individually, and discourse analysis was processed anonymously.
RESULTS: We carried out a quantitative (SRL) and a qualitative approach (FG). The discourse analysis and roadmap were sent individually to each expert for approval.
CONCLUSIONS: The potential of Precision Medicine has not been fulfilled in Spain. While several regional initiatives are in place, a national plan or strategy around Precision Medicine and use of biomarkers is lacking. In a general context of rapid progress at a global and European level, including the 2021 Europe's Beating Cancer Plan, it is time to define and implement a National Plan to make the promise come true. While some comparable countries within Europe - such as the UK or France - are mature enough to adopt such strategies, in Spain there is still a long way to go. We consider that the different strands of work outlined in the Roadmap can be used as basis for such purpose.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 26(2024), 4 vom: 02. Apr., Seite 985-990 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mestre-Ferrándiz, Jorge [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 02.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12094-023-03338-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366971069 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366971069 | ||
| 003 | DE-627 | ||
| 005 | 20240403000044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12094-023-03338-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1361.xml |
| 035 | |a (DE-627)NLM366971069 | ||
| 035 | |a (NLM)38206517 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mestre-Ferrándiz, Jorge |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a PURPOSE: Biomarkers as screening for precision medicine is a fundamental step. The purpose of this article is twofold. First, to highlight the existing barriers in the implementation of Precision Medicine in Spain, with a special emphasis on barriers in access to the determination of biomarkers. Second, to provide a Roadmap that can help implement Precision Medicine equitably at the national level and optimize the use of biomarkers | ||
| 520 | |a METHODS: A systematic review of literature (SRL) and a focus group (FG) with multidisciplinary experts has been carried out in 2023. Participants were contacted individually, and discourse analysis was processed anonymously | ||
| 520 | |a RESULTS: We carried out a quantitative (SRL) and a qualitative approach (FG). The discourse analysis and roadmap were sent individually to each expert for approval | ||
| 520 | |a CONCLUSIONS: The potential of Precision Medicine has not been fulfilled in Spain. While several regional initiatives are in place, a national plan or strategy around Precision Medicine and use of biomarkers is lacking. In a general context of rapid progress at a global and European level, including the 2021 Europe's Beating Cancer Plan, it is time to define and implement a National Plan to make the promise come true. While some comparable countries within Europe - such as the UK or France - are mature enough to adopt such strategies, in Spain there is still a long way to go. We consider that the different strands of work outlined in the Roadmap can be used as basis for such purpose | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Policy Roadmap | |
| 650 | 4 | |a Precision Medicine | |
| 650 | 4 | |a Spain | |
| 650 | 4 | |a Oncology | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Franch Camino, Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Hidalgo, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Del Llano Núñez-Cortés, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Del Llano Señarís, Juan Ernesto |e verfasserin |4 aut | |
| 700 | 1 | |a Lumbreras, Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Beas Pedraza, David |e verfasserin |4 aut | |
| 700 | 1 | |a Nuño-Solinís, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Paz-Ares, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Ramón Y Cajal, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Miguel Javier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico |d 2005 |g 26(2024), 4 vom: 02. Apr., Seite 985-990 |w (DE-627)NLM155341065 |x 1699-3055 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:4 |g day:02 |g month:04 |g pages:985-990 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12094-023-03338-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 4 |b 02 |c 04 |h 985-990 | ||